ID: ALA4483681

Max Phase: Preclinical

Molecular Formula: C25H35Cl2N3O3

Molecular Weight: 496.48

Molecule Type: Unknown

Representations

Canonical SMILES:  CC(C)(C)OC(=O)N1CCN(C(=O)Cc2ccc(Cl)c(Cl)c2)[C@@H]2[C@@H](N3CCCC3)CCC[C@@H]21

Standard InChI:  InChI=1S/C25H35Cl2N3O3/c1-25(2,3)33-24(32)29-13-14-30(22(31)16-17-9-10-18(26)19(27)15-17)23-20(7-6-8-21(23)29)28-11-4-5-12-28/h9-10,15,20-21,23H,4-8,11-14,16H2,1-3H3/t20-,21-,23+/m0/s1

Standard InChI Key:  QYKOMVKBDKOREW-QNWVGRARSA-N

Molecule Features

Natural Product: No

Oral: No

Chemical Probe: No

Parenteral: No

Molecule Type: Unknown

Topical: No

First In Class: No

Black Box: No

Chirality: No

Availability: No

Prodrug: No

Properties

Molecular Weight: 496.48

Molecular Weight (Monoisotopic): 495.2055

AlogP: 5.00

#Rotatable Bonds: 3

Polar Surface Area: 53.09

Molecular Species: BASE

HBA: 4

HBD: 0

#RO5 Violations: 1

HBA (Lipinski): 6

HBD (Lipinski): 0

#RO5 Violations (Lipinski): 1

CX Acidic pKa:

CX Basic pKa: 8.98

CX LogP: 4.66

CX LogD: 3.07

Aromatic Rings: 1

Heavy Atoms: 33

QED Weighted: 0.59

Np Likeness Score: -0.67

References

1. Tangherlini G, Kalinin DV, Schepmann D, Che T, Mykicki N, Ständer S, Loser K, Wünsch B..  (2019)  Development of Novel Quinoxaline-Based κ-Opioid Receptor Agonists for the Treatment of Neuroinflammation.,  62  (2): [PMID:30543421] [10.1021/acs.jmedchem.8b01609]

Source

Source(1):

• Scientific Literature